公开(公告)号：US20230250105A1

公开(公告)日：2023-08-10

申请号：US18175030

申请日：2023-02-27

Applicant: UCB Biopharma SRL ,  SANOFI

Inventor： Daniel Christopher Brookings ,  Teresa De Haro Garcia ,  Yann Foricher ,  Helen Tracey Horsley ,  Martin Clive Hutchings ,  James Andrew Johnson ,  Malcolm Maccoss ,  Mengyang Xuan ,  Zhaoning Zhu

IPC: C07D487/18

CPC classification number: C07D487/18 ,  C07B2200/05

Abstract: A compound of formula (I) as defined herein, or a pharmaceutically acceptable salt thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

公开(公告)号：US20210252012A1

公开(公告)日：2021-08-19

申请号：US17176018

申请日：2021-02-15

Applicant: UCB Biopharma SRL ,  SANOFI

Inventor： Daniel Christopher Brookings ,  Teresa De Haro Garcia ,  Yann Foricher ,  Helen Tracey Horsley ,  Martin Clive Hutchings ,  James Andrew Johnson ,  Malcolm Maccoss ,  Mengyang Xuan ,  Zhaoning Zhu

IPC: A61K31/55 ,  C07D487/18

Abstract: A compound of formula (I) as defined herein, or a pharmaceutically acceptable salt thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

公开(公告)号：US11091474B2

公开(公告)日：2021-08-17

申请号：US16480251

申请日：2018-01-23

Applicant: UCB Biopharma SRL

Inventor： Adrian Hall ,  Malcolm Maccoss

IPC: C07D417/14

Abstract: The present invention relates to certain bis-heteroaryl compounds, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto-temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer including melanoma.

公开(公告)号：US10975066B2

公开(公告)日：2021-04-13

申请号：US15748154

申请日：2016-07-29

Applicant: UCB Biopharma SRL

Inventor： Wolfgang Wrasidlo ,  Emily M. Stocking ,  Adrian Hall ,  Malcolm Maccoss

IPC: C07D417/12 ,  C07D417/14 ,  C07D487/08 ,  C07D403/12 ,  C07D403/14 ,  C07D413/12 ,  C07D413/14 ,  A61P25/28

Abstract: The present invention relates to certain bis-heteroaryl compounds, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto-temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer including melanoma.

公开(公告)号：US11479546B2

公开(公告)日：2022-10-25

申请号：US17044550

申请日：2019-04-02

Applicant: UCB Biopharma SRL

Inventor： Teresa De Haro Garcia ,  Lloyd Malcolm King ,  Martin Alexander Lowe ,  Malcolm Maccoss ,  Richard David Taylor ,  Zhaoning Zhu

IPC: A61P33/06 ,  C07D403/12 ,  C07D493/08 ,  C07D471/04 ,  C07D239/22 ,  C07D401/12 ,  C07D413/14 ,  C07D405/06 ,  C07D405/14 ,  C07D405/04

Abstract: The application relates to a series of 2-imino-6-methylhexahydropyrimidin-4-one derivatives and 3-imino-5-methyl-1,2,4-thiadiazinane 1,1-dioxide derivatives of formula (I), substituted by an arylaminophenyl or heteroarylaminophenyl moiety. The compounds are potent inhibitors of the growth and propagation of the Plasmodium falciparum parasite in human blood and thus useful as pharmaceutical agents for the treatment of malaria.

公开(公告)号：US10980814B2

公开(公告)日：2021-04-20

申请号：US16497217

申请日：2018-04-24

Applicant: UCB Biopharma SRL ,  SANOFI

Inventor： Daniel Christopher Brookings ,  Teresa De Haro Garcia ,  Yann Foricher ,  Helen Tracey Horsley ,  Martin Clive Hutchings ,  James Andrew Johnson ,  Malcolm Maccoss ,  Mengyang Xuan ,  Zhaoning Zhu

IPC: C07D487/18 ,  A61K31/55

Abstract: Disclosed herein are compounds of formula (I) and pharmaceutically acceptable salt thereof, wherein variables X, R1, R2, and R3 are defined herein. These compounds are potent modulators of human TNFα activity and, accordingly, of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

公开(公告)号：US20210094941A1

公开(公告)日：2021-04-01

申请号：US17044550

申请日：2019-04-02

Applicant: UCB Biopharma SRL

Inventor： Teresa De Haro Garcia ,  Lloyd Malcolm King ,  Martin Alexander Lowe ,  Malcolm Maccoss ,  Richard David Taylor ,  Zhaoning Zhu

IPC: C07D405/14 ,  C07D239/22 ,  C07D405/04 ,  C07D471/04 ,  C07D413/14 ,  C07D401/12 ,  C07D403/12 ,  C07D493/08 ,  C07D405/06

Abstract: The application relates to a series of 2-imino-6-methylhexahydropyrimidin-4-one derivatives and 3-imino-5-methyl-1,2,4-thiadiazinane 1,1-dioxide derivatives of formula (I), substituted by an arylaminophenyl or heteroarylaminophenyl moiety. The compounds are potent inhibitors of the growth and propagation of the Plasmodium falciparum parasite in human blood and thus useful as pharmaceutical agents for the treatment of malaria.

公开(公告)号：US10889584B2

公开(公告)日：2021-01-12

申请号：US16480254

申请日：2018-01-23

Applicant: UCB Biopharma SRL

Inventor： Adrian Hall ,  Laurent Provins ,  Malcolm Maccoss

IPC: C07D471/04 ,  C07D487/04 ,  C07D498/04 ,  A61K31/496 ,  A61K31/501 ,  A61K31/506 ,  A61P25/28

Abstract: The present invention relates to certain bicyclic bis-heteroaryl compounds of Formula (I), pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto-temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer including melanoma.